Iron Deficiency Anemia Therapy Market to Reach USD 10.94 Billion by 2034, Driven by Rising Cases and Expanding R&D Activities

The global iron deficiency anemia therapy market size is calculated at USD 5.64 billion in 2025 and is expected to reach around USD 10.94 billion by 2034, growing at a CAGR of 7.64% for the forecasted period.

Ottawa, Nov. 03, 2025 (GLOBE NEWSWIRE) -- The global iron deficiency anemia therapy market size was valued at USD 5.24 billion in 2024 and is predicted to hit around USD 10.94 billion by 2034, rising at a 7.64% CAGR, a study published by Towards Healthcare a sister firm of Precedence Research.

A rise in cases of iron deficiency anemia and the expansion of research and development activities are fueling the global market.

The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ https://www.towardshealthcare.com/download-sample/5430

Key Takeaways

North America registered dominance in the market in 2024.
Asia-Pacific is expected to be the fastest-growing region in the studied years.
By therapy type, the parenteral iron therapy segment led the market in 2024.
By therapy type, the oral iron therapy segment is expected to witness rapid expansion during 2025-2034.
By age group, the adults segment dominated the iron deficiency anemia therapy market in 2024.
By age group, the pediatric segment is expected to grow at the fastest CAGR in the upcoming years.
By end-user, the hospitals segment was dominant in the market in 2024.
By end-user, the home healthcare segment is expected to register the fastest growth during 2025-2034.

A Surge in IV Formulations: What is Empowering Iron Deficiency Anemia Therapy?

Significantly, the market comprises various oral iron supplements in frequent instances, but nowadays, they are exploring safer and more convenient intravenous (IV) iron formulations like ferric carboxymaltose. The iron deficiency anemia therapy market is propelled by the increasing cases of IDA, majorly in women, children, and the elderly, and the rising awareness regarding these concerns and their treatments. Researchers are studying the combination therapy, which includes these therapies with therapies that can stimulate red blood cell production (erythropoiesis-stimulating agents).

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

What are the Crucial Drivers in the Market?

The growing prevalence of chronic kidney disease, congestive heart failure, and inflammatory bowel disease is fueling the development of IDA among all populations. This further drives demand for advanced IDA therapies. The market is further expanding with consistent research and development, which is emphasising the establishment of more effective oral iron supplements with minimal gastrointestinal side effects.

Trends in the Iron Deficiency Anemia Therapy Market

In September 2025, the World Anemia Awareness partnered with the Society for the Advancement of Patient Blood Management (SABM) to raise global focus on blood health.
In August 2025, Danone India and, Government of Maharashtra partnered to boost awareness on iron deficiency and protein intake among Mumbaikars.

What is the Major Challenge in the Market?

The iron deficiency anemia therapy market is facing limitations due to minimal patient adherence to treatment, side effects from oral supplements, and the presence of comorbidities and other micronutrient deficiencies that complicate treatment.

Regional Analysis

What Made North America Dominant in the Market in 2024?

In 2024, North America accounted for the largest share by 37% of the market. This region is having a major rise in the rate of IDA, mainly among pregnant women, the elderly, and individuals with chronic diseases, including chronic kidney disease and inflammatory bowel disease. Whereas, the U.S. Preventive Services Task Force (USPSTF) recommended against routine screening for iron deficiency in asymptomatic pregnant women, quoting insufficient evidence related to the impact on maternal and infant health.

For instance,

In March 2025, ACCRUFeR (ferric maltol) was made available in Canada as a prescription oral treatment for iron deficiency anemia.

Download the single region market report @ https://www.towardshealthcare.com/checkout/5430

U.S. Market Growth for Iron Deficiency Anemia Therapy:

In the United States, the iron deficiency anemia therapy market is experiencing steady expansion, driven by increasing awareness, advanced healthcare infrastructure, and rising prevalence among specific groups such as women, the elderly, and patients with chronic diseases. The market is supported by strong screening programs and the availability of innovative treatment options, including newer oral and intravenous iron formulations that reduce side effects and improve patient compliance. The growing adoption of parenteral iron therapies and ongoing clinical research into improved iron delivery systems are also contributing to sustained market growth. Overall, the U.S. market remains mature but continues to offer significant opportunities as technological advancements and patient-focused treatments gain traction.

Asia Pacific Iron Deficiency Anemia Therapy Market Analysis:

In the future, the Asia Pacific is anticipated to expand rapidly in the iron deficiency anemia therapy market. A rise in IDA incidences is mainly driven by poor dietary intake, genetic factors, and chronic conditions among the ASAP population. For this, various countries' governments are promoting different government campaigns and public health initiatives to raise awareness about these concerns.

For instance,

In September 2025, India implemented the Anemia Mukt Bharat strategy for the reduction of anaemia among six beneficiary age groups: children (6-59 months), children (5-9 years), adolescents (10-19 years), pregnant and lactating women and women of reproductive age group (15-49 years) in the life cycle.

India Market Growth for Iron Deficiency Anemia Therapy

In India, the iron deficiency anemia therapy market is growing rapidly due to a combination of public health initiatives, rising healthcare access, and increasing awareness about the importance of early diagnosis and treatment. Government-led programs targeting women and children have significantly boosted demand for iron and folic acid supplementation, while hospitals and clinics are expanding the use of intravenous iron formulations to treat moderate to severe cases. The country’s large population base, coupled with ongoing improvements in healthcare infrastructure, is fueling strong market expansion. However, challenges such as affordability, limited access in rural regions, and low adherence to long-term therapy still constrain optimal growth. Despite these hurdles, India remains one of the most promising markets for iron deficiency anemia therapies in the coming years.

Become a valued research partner with us - https://www.towardshealthcare.com/schedule-meeting

Segmental Insights

By Therapy Type Analysis:

Which Therapy Type Led the Iron Deficiency Anemia Therapy Market in 2024?

The parenteral iron therapy segment captured a dominant share of the market in 2024. This is the most efficacious and rapid therapy used in numerous chronic diseases, as well as ongoing breakthroughs in IV formulations are enhancing safety and lowering side effects. Alongside, they possess wider beneficial effects in heart failure, certain bariatric surgery patients, and those with RLS. Recently, the US FDA approved a generic version of iron sucrose injection, USP, for the treatment of IDA in adults and pediatric patients (2 years and older) with CKD.

Whereas the oral iron therapy segment is predicted to grow at a rapid CAGR. Its affordability and ease of administration are making it the patient's preference. Many pharmaceutical companies are leveraging active investment in liposomal iron and ferric maltol to achieve better absorption and minimal gastrointestinal side effects. Recent studies have described an alternate-day dosing approach to enhance fractional iron absorption.

By Age Group Analysis:

Why did the Adults Segment Dominate the Market in 2024?

In 2024, the adults segment held the biggest share of the iron deficiency anemia therapy market. This mainly consists of women of childbearing age, pregnant women, and those with chronic diseases, including chronic kidney disease or cancer. In the growing heart failure cases, IV iron is recommended for iron-deficient patients with HF (NYHA class II or III) with its improved quality of life, functional capacity, and lowered rehospitalizations.

On the other hand, the pediatric segment is anticipated to witness the fastest growth. Because of poor dietary intake, infants and toddlers (under 5) and adolescents are facing IDA. Nowadays, different regions are bolstering iron supplementation and nutrition programs. Expanded dietary consultations suggest enriching the empty stomach with vitamin C-rich foods and reducing excessive cow’s milk consumption.

Get the latest insights on life science industry segmentation with our Annual Membership: https://www.towardshealthcare.com/get-an-annual-membership

By End-user Analysis:

What Made the Hospitals Segment Dominant in the Market in 2024?

The hospitals segment registered dominance with a major revenue share of the iron deficiency anemia therapy market in 2024. They possess well-equipped management solutions for anemia associated with chronic conditions. Also, they offer a setting for complex cases that need a team of specialists, advanced diagnostics, and comprehensive treatment plans. The emergence of hospital-based therapies gives better reimbursement and insurance coverage, which is also impacting the segmental growth.

Moreover, the home healthcare segment is predicted to grow at a rapid CAGR. The globe is shifting towards convenient approaches, with affordability and reduced hospital visits boosting the adoption of home healthcare. Continuous advances in telehealth and remote patient monitoring are supporting healthcare providers in managing and monitoring patients' iron levels and conditions.

What are the Key Developments in the Iron Deficiency Anemia Therapy Market?

In June 2025, Wanbury Limited launched 'Wanbury Cred', a novel iron supplement created to eliminate iron deficiency and anaemia.
In July 2025, One A Day®, the multivitamin and supplement brand, launched first of its first-of-its-kind One A Day® Kids Multi with Iron to support filling nutrient gaps in kids.

Browse More Insights of Towards Healthcare:

The global cell and gene therapy manufacturing quality control (QC) market was valued at USD 2.66 billion in 2024, increased to USD 3.11 billion in 2025, and is projected to reach approximately USD 12.35 billion by 2034, expanding at a CAGR of 16.89% from 2025 to 2034.

The global cell and gene therapy (CGT) pharmaceuticals market recorded a valuation of USD 16.75 billion in 2024, rising to USD 19.91 billion in 2025, and is anticipated to achieve nearly USD 91.56 billion by 2034, growing at a CAGR of 18.93% throughout the forecast period.

The global cell and gene therapy cold chain logistics market was valued at USD 1.89 billion in 2024, expanded to USD 2.19 billion in 2025, and is expected to reach around USD 8.06 billion by 2034, progressing at a CAGR of 15.64% between 2025 and 2034.

The global cell and gene therapy drug delivery devices market is witnessing strong momentum and is poised for substantial revenue growth, potentially reaching several hundred million dollars by 2034, driven by advancements in precision delivery technologies and increased CGT product approvals.

The global cell and gene therapy contract research organization (CRO) market size was estimated at USD 4.90 billion in 2024, projected to reach USD 5.39 billion in 2025, and expected to hit approximately USD 12.59 billion by 2034, registering a CAGR of 9.9% over the forecast timeline.

The global cell and gene therapy (CGT) biomanufacturing market reached USD 14.03 billion in 2024, increased to USD 15.63 billion in 2025, and is forecasted to attain around USD 41.41 billion by 2034, expanding at a CAGR of 11.43%.

The global gene therapy cell culture media market was valued at USD 193.45 billion in 2024, projected to rise to USD 214.42 billion in 2025, and is set to exceed USD 541.42 billion by 2034, growing at a CAGR of 10.84%.

The global gene therapy for sickle cell disease market is also witnessing robust expansion, with revenue projected to climb into the hundreds of millions by 2034, supported by breakthroughs in CRISPR-based and viral vector therapies.

The global cell and gene therapy isolator market was valued at USD 1.35 billion in 2024, expanded to USD 1.52 billion in 2025, and is forecasted to reach approximately USD 4.47 billion by 2034, exhibiting a CAGR of 12.54% during the forecast period.

Meanwhile, the global proton therapy systems market registered a valuation of USD 1.52 billion in 2024, rose to USD 1.66 billion in 2025, and is expected to surpass USD 3.72 billion by 2034, advancing at a CAGR of 9.44% between 2025 and 2034.

Iron Deficiency Anemia Therapy Market Key Players List

AbbVie, Inc.
Akebia Therapeutics
AMAG Pharmaceuticals
CSL Vifor
Daiichi Sankyo Company
Emcure Pharmaceuticals
Ironic Biotech
Johnson & Johnson
Kye Pharmaceuticals
Pharmacosmos Therapeutics
Shield Therapeutics
Teva Pharmaceuticals

Segments Covered in the Report

By Therapy Type

Parenteral Iron Therapy
Oral Iron Therapy
Red Blood Cell Transfusion
Others

By Age Group

Adults
Pediatric
Geriatric

By End-User

Hospitals
Home Healthcare
Clinics

By Region

North America
- US
- Canada
Asia Pacific
- China
- Japan
- India
- South Korea
- Thailand
Europe
- Germany
- UK
- France
- Italy
- Spain
- Sweden
- Denmark
- Norway
Latin America
- Brazil
- Mexico
- Argentina
Middle East and Africa (MEA)
- South Africa
- UAE
- Saudi Arabia
- Kuwait

Immediate Delivery Available | Buy This Premium Research @ https://www.towardshealthcare.com/checkout/5430

Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.

Access the Dashboard: https://www.towardshealthcare.com/access-dashboard

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth.

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

Europe Region: +44 778 256 0738

North America Region: +1 8044 4193 44

APAC Region: +91 9356 9282 04

Web: https://www.towardshealthcare.com

Our Trusted Data Partners

Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.